{"id":"https://openalex.org/W1590925586","doi":"https://doi.org/10.1111/j.1365-2710.2010.01235.x","title":"Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects","display_name":"Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects","publication_year":2010,"publication_date":"2010-12-05","ids":{"openalex":"https://openalex.org/W1590925586","doi":"https://doi.org/10.1111/j.1365-2710.2010.01235.x","mag":"1590925586","pmid":"https://pubmed.ncbi.nlm.nih.gov/21128991"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2710.2010.01235.x","doi":"https://doi.org/10.1111/j.1365-2710.2010.01235.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2710.2010.01235.x","pdf_url":null,"source":{"id":"https://openalex.org/S156693432","display_name":"Journal of Clinical Pharmacy and Therapeutics","issn_l":"0269-4727","issn":["0269-4727","1365-2710"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Pharmacy and Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5013609146","display_name":"Fenglei Huang","orcid":"https://orcid.org/0000-0002-0642-9401","observed_orcids":["https://orcid.org/0000-0002-0642-9401"]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"F. Huang","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877-0368, USA. fenglei.huang@boehringer-ingelheim.com","Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877-0368, USA. fenglei.huang@boehringer-ingelheim.com","institution_ids":["https://openalex.org/I4210160255"]},{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA,","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":null,"display_name":"L. Allen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. Allen","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016570350","display_name":"David B. Huang","orcid":"https://orcid.org/0000-0001-8228-7911","observed_orcids":["https://orcid.org/0000-0001-8228-7911","https://orcid.org/0000-0002-8342-3193"]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"D. B. Huang","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025297038","display_name":"Fong Siew Moy","orcid":"https://orcid.org/0000-0003-4663-4618","observed_orcids":["https://orcid.org/0000-0003-4663-4618"]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"F. Moy","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041375594","display_name":"Richard Vinisko","orcid":"https://orcid.org/0000-0001-9045-3027","observed_orcids":["https://orcid.org/0000-0001-9045-3027"]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Vinisko","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101536668","display_name":"Thuy Nguyen","orcid":"https://orcid.org/0000-0001-6692-2110","observed_orcids":["https://orcid.org/0000-0001-6692-2110"]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T. Nguyen","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026841475","display_name":"Lois Rowland","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. Rowland","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA,","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045416293","display_name":"Thomas R. MacGregor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"T. R. MacGregor","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065219767","display_name":"Mark A. Castles","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"M. A. Castles","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5067081307","display_name":"Patrick A. Robinson","orcid":"https://orcid.org/0000-0001-9237-9414","observed_orcids":["https://orcid.org/0000-0001-9237-9414"]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Robinson","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA","institution_ids":["https://openalex.org/I4210160255"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5016570350","https://openalex.org/A5025297038","https://openalex.org/A5045416293","https://openalex.org/A5065219767"],"corresponding_institution_ids":["https://openalex.org/I4210160255"],"apc_list":{"value":2700,"currency":"USD","value_usd":2700},"apc_paid":null,"fwci":0.2066,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.59116553,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"37","issue":"1","first_page":"81","last_page":"88"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.7080000042915344},{"id":"https://openalex.org/keywords/pharmacokinetic-interactions","display_name":"pharmacokinetic interactions","score":0.8080000281333923},{"id":"https://openalex.org/keywords/lamivudine","display_name":"lamivudine","score":0.9509999752044678},{"id":"https://openalex.org/keywords/zidovudine","display_name":"zidovudine","score":0.996999979019165},{"id":"https://openalex.org/keywords/non-nucleoside-reverse-transcriptase-inhibitors","display_name":"non-nucleoside reverse transcriptase inhibitors","score":0.9380000233650208},{"id":"https://openalex.org/keywords/hiv-1","display_name":"HIV-1","score":0.6800000071525574},{"id":"https://openalex.org/keywords/antiretroviral-therapy","display_name":"antiretroviral therapy","score":0.734000027179718},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.5379999876022339},{"id":"https://openalex.org/keywords/people-living-with-hiv","display_name":"people living with HIV","score":0.597000002861023},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.4569999873638153},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5360000133514404}],"concepts":[{"id":"https://openalex.org/C2777869810","wikidata":"https://www.wikidata.org/wiki/Q422631","display_name":"Lamivudine","level":4,"score":0.9190733432769775},{"id":"https://openalex.org/C2780216070","wikidata":"https://www.wikidata.org/wiki/Q198504","display_name":"Zidovudine","level":4,"score":0.847018301486969},{"id":"https://openalex.org/C2779298103","wikidata":"https://www.wikidata.org/wiki/Q422618","display_name":"Ritonavir","level":5,"score":0.7995079159736633},{"id":"https://openalex.org/C2777351918","wikidata":"https://www.wikidata.org/wiki/Q421559","display_name":"Reverse-transcriptase inhibitor","level":5,"score":0.7838083505630493},{"id":"https://openalex.org/C2909970146","wikidata":"https://www.wikidata.org/wiki/Q421559","display_name":"Nucleoside Reverse Transcriptase Inhibitor","level":5,"score":0.6926695704460144},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.6230407357215881},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5772014260292053},{"id":"https://openalex.org/C156719811","wikidata":"https://www.wikidata.org/wiki/Q28774","display_name":"Reverse transcriptase","level":4,"score":0.5096409320831299},{"id":"https://openalex.org/C2777333352","wikidata":"https://www.wikidata.org/wiki/Q2689559","display_name":"Nucleoside analogue","level":3,"score":0.4503544270992279},{"id":"https://openalex.org/C2776543447","wikidata":"https://www.wikidata.org/wiki/Q28734","display_name":"Nucleoside","level":2,"score":0.4414726495742798},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.4004896879196167},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3915441036224365},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.34913498163223267},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3330919146537781},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.25410711765289307},{"id":"https://openalex.org/C2776452011","wikidata":"https://www.wikidata.org/wiki/Q311463","display_name":"Sida","level":4,"score":0.17994588613510132},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.16469740867614746},{"id":"https://openalex.org/C2780727368","wikidata":"https://www.wikidata.org/wiki/Q1928978","display_name":"Viral disease","level":3,"score":0.1515187919139862},{"id":"https://openalex.org/C67705224","wikidata":"https://www.wikidata.org/wiki/Q11053","display_name":"RNA","level":3,"score":0.0879906415939331},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.08576637506484985},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.06494057178497314},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.04827725887298584},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C2780593183","wikidata":"https://www.wikidata.org/wiki/Q6844","display_name":"Hepatitis B virus","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001381","descriptor_name":"Azepines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001381","descriptor_name":"Azepines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001381","descriptor_name":"Azepines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004338","descriptor_name":"Drug Combinations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D015215","descriptor_name":"Zidovudine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015215","descriptor_name":"Zidovudine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D015215","descriptor_name":"Zidovudine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D017320","descriptor_name":"HIV Protease Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D019259","descriptor_name":"Lamivudine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019259","descriptor_name":"Lamivudine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019259","descriptor_name":"Lamivudine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D019438","descriptor_name":"Ritonavir","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019438","descriptor_name":"Ritonavir","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019438","descriptor_name":"Ritonavir","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1365-2710.2010.01235.x","doi":"https://doi.org/10.1111/j.1365-2710.2010.01235.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2710.2010.01235.x","pdf_url":null,"source":{"id":"https://openalex.org/S156693432","display_name":"Journal of Clinical Pharmacy and Therapeutics","issn_l":"0269-4727","issn":["0269-4727","1365-2710"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Pharmacy and Therapeutics","raw_type":"journal-article"},{"id":"pmid:21128991","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21128991","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical pharmacy and therapeutics","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320306257","display_name":"Boehringer Ingelheim","ror":"https://ror.org/05kffp613"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":33,"referenced_works":["https://openalex.org/W166442292","https://openalex.org/W299209873","https://openalex.org/W1599625107","https://openalex.org/W2001967406","https://openalex.org/W2026323517","https://openalex.org/W2028586698","https://openalex.org/W2036597966","https://openalex.org/W2040620437","https://openalex.org/W2048951981","https://openalex.org/W2057392755","https://openalex.org/W2063389973","https://openalex.org/W2074684937","https://openalex.org/W2077014185","https://openalex.org/W2078572618","https://openalex.org/W2079573278","https://openalex.org/W2080198736","https://openalex.org/W2090256940","https://openalex.org/W2095273553","https://openalex.org/W2098137059","https://openalex.org/W2115768301","https://openalex.org/W2118492018","https://openalex.org/W2134197341","https://openalex.org/W2137166365","https://openalex.org/W2137286226","https://openalex.org/W2143910776","https://openalex.org/W2146749308","https://openalex.org/W2322707374","https://openalex.org/W4232932066","https://openalex.org/W4240002281","https://openalex.org/W4253549505","https://openalex.org/W4300745548","https://openalex.org/W6610620921","https://openalex.org/W6635933079"],"related_works":["https://openalex.org/W2032208061","https://openalex.org/W1599625107","https://openalex.org/W2063389973","https://openalex.org/W2118492018","https://openalex.org/W2169279535","https://openalex.org/W2016087474","https://openalex.org/W1689875947","https://openalex.org/W2000960601","https://openalex.org/W7097868770","https://openalex.org/W2083580679"],"abstract_inverted_index":{"WHAT":[0,281],"IS":[1,282],"KNOWN":[2],"AND":[3,204,284],"OBJECTIVE:":[4],"BILR":[5,77,111,151,186,197,209,257,289,301],"355":[6,78,112,182,187,198,290,302],"is":[7,35,42,270],"a":[8,36,48,85,245,251,295,304],"second":[9],"generation":[10],"non-nucleoside":[11],"reverse":[12,38],"transcriptase":[13,39],"inhibitor.":[14,40],"It":[15,41],"has":[16],"shown":[17],"promising":[18],"in":[19,45,174,179,185,244,248,254,262,294,298,307],"vitro":[20],"anti-HIV-1":[21],"activities":[22],"and":[23,79,109,113,138,194,213,220,250,264,303],"favourable":[24],"human":[25],"pharmacokinetic":[26,73,141,161],"properties":[27],"after":[28],"co-administration":[29,207],"with":[30,122,168,191,208,241,291],"ritonavir":[31],"(RTV).":[32],"Lamivudine":[33],"(3TC)":[34],"nucleoside":[37],"excreted":[43],"predominantly":[44],"urine":[46],"by":[47,218],"transporter-mediated":[49],"pathway.":[50],"These":[51],"two":[52],"drugs":[53],"are":[54],"likely":[55],"to":[56,60,69,273,300,309],"be":[57],"given":[58,98,150],"together":[59],"HIV-infected":[61],"patients.":[62],"The":[63,160,259],"objective":[64],"of":[65,215,228,236,266,268,275,279,288],"this":[66,123],"study":[67],"was":[68,84,200,230,238],"investigate":[70],"any":[71],"steady-state":[72],"interactions":[74],"between":[75],"RTV-boosted":[76],"3TC/zidovudine":[80],"(ZDV).":[81],"METHODS:":[82],"This":[83],"randomized,":[86],"open":[87],"label,":[88],"prospective":[89],"study.":[90],"In":[91,143],"group":[92,144,164,171,184],"A,":[93],"39":[94],"healthy":[95,147],"subjects":[96,148,173],"were":[97,120,133,149,166],"3TC/ZDV":[99,242,292],"(150":[100,153],"mg/300":[101],"mg)":[102,119,155],"twice":[103],"daily":[104],"(b.i.d.)":[105],"for":[106,125,140,157,256],"7":[107,128,137,158],"days,":[108],"then":[110],"RTV":[114],"(BILR":[115,181],"355/r,":[116,210],"150":[117],"mg/100":[118,154],"co-administered":[121],"regimen":[124,199],"an":[126],"additional":[127],"days.":[129,159],"Intensive":[130],"blood":[131],"samples":[132],"taken":[134],"on":[135],"days":[136],"14":[139],"assessments.":[142],"B,":[145],"12":[146],"355/r":[152],"b.i.d.":[156],"data":[162,169],"from":[163,170],"B":[165,172],"pooled":[167],"other":[175],"similar":[176],"studies":[177,190],"performed":[178],"parallel":[180],"alone":[183],"drug-drug":[188],"interaction":[189],"tipranavir,":[192],"lopinavir/RTV,":[193],"emtricitabine/tenofovir":[195],"DF;":[196],"the":[201,211,223,234],"same).":[202],"RESULTS":[203],"DISCUSSION:":[205],"After":[206],"AUC(12,ss)":[212,249],"C(max,ss)":[214,255],"3TC":[216,229,269],"increased":[217],"45%":[219,305],"24%,":[221],"respectively;":[222],"elimination":[224],"half-life":[225],"(t(1/2)":[226],",ss)":[227],"significantly":[231],"increased.":[232],"However,":[233],"pharmacokinetics":[235],"ZDV":[237],"unchanged.":[239],"Co-administration":[240],"resulted":[243,293],"22%":[246],"decrease":[247,253,297],"20%":[252],"355.":[258],"observed":[260],"increase":[261,306],"exposure":[263,299,308],"prolongation":[265],"t(1/2,ss)":[267],"potentially":[271],"related":[272],"inhibition":[274],"OCT-mediated":[276],"urinary":[277],"excretion":[278],"3TC.":[280,310],"NEW":[283],"CONCLUSION:":[285],"Concomitant":[286],"administration":[287],"modest":[296]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}